Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Stayble Therapeutics recruits VP CMC and Regulatory Affairs

Stayble Therapeutics strengthens the organization by appointing Dr. Sara Richardson in the new role of VP CMC and Regulatory Affairs. Dr. Richardson's expertise and experience in manufacturing issues (CMC) and regulatory applications will be very valuable for the company's future plans and the clinical development of the drug candidate STA363. BioStock reached out to Dr. Richardson for a comment.Read the full article at biostock.se: https://www.biostock.se/en/stayble-therapeutics-recruits-vp-cmc-and-regulatory-affairs/This is a press release from BioStock - Connecting Innovation &

Nine West and Polygiene apparel sold out in successful Korean Hyundai Home Shopping campaign

The new Polygiene partner Nine West Apparel recently launched a collection of New York Lounge Wear with Polygiene Stays Fresh technology broadcasted by Hyundai Home Shopping in Korea. The successful collection sold out quickly and a new collection is planned for the fall and winter season 2021. Image©: Nine West Apparel   The global fashion brand Nine West recently launched apparel for the first time in Korea. The lounge wear collection with women and men styles was introduced in collaboration with Luna, a well-known member of the Korean group FX as their muse, presenting an

World leading rheumatology authority Professor Costantino Pitzalis collaborates with Cyxone on Rabeximod Phase 2b study

Cyxone announce today that the company has entered into a collaboration with Professor Costantino Pitzalis, Versus Arthritis Professor of Rheumatology at the William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. As a world leading expert in pathobiology, translational research and biopsy driven clinical trials, Professor Pitzalis brings invaluable expertise and know-how in rheumatoid arthritis (RA) clinical trial design and will be pivotal in Cyxone’s planned clinical trial in RA indication for the compound Rabeximod.

Notice of annual general meeting in Cyxone AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail.The shareholders in Cyxone AB, Reg. No. 559020-5471 (“Cyxone”), are hereby invited to the annual general meeting to be held at the premises of Clarion Hotel Malmö Live at Dag Hammarskjölds torg 2 in Malmö, Sweden on Thursday 3 June 2021 at 13:00 CET. Important information about the current situation regarding covid-19 and about attending the annual general meeting by proxy Due to covid-

Reminder: C-RAD Web Presentation Interim Report Q1 2021 and AGM speech

Reminder: C-RAD Web Presentation Interim Report Q1 2021 Invitation to join the presentation of C-RAD’s first quarter 2021. CEO Tim Thurn will also give his Annual General Meeting speech at this event. The AGM is held on May 7 but without any presence from shareholders or other parties, as communicated previously in the call for the AGM. Date: Thursday May 7, 2021 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Interim Report Q1 2021 /AGM speech Procedure: Please register online through the website:   https://us06web.zoom.us/webinar/register/WN_xs_

Bioservo Technologies AB Interim Report January – March 2021

First quarter in figures · Net sales of SEK 1.5 M (3.0) · EBITDA of SEK -7.8 M (-6.6) · EBIT of SEK -9.0 M (-7.5) · Earnings for the period amounted to SEK -9.0 M (-7.5) · Earnings per share before and after dilution amounted to SEK -0.57 (-0.53) · Cash flow from operating activities for the period amounted to SEK -7.7 M (-6.2) · On 31 March, cash and cash equivalents were SEK 44.7 M (50.3) Significant events during the period · Bioservo obtained financing of SEK 5 million within the Horizon 2020 framework to develop the next generation of rehabilitative and

Nordnet: Monthly statistics April

In April, 5,652,100 trades were made in listed financial instruments among Nordnet’s customers in Sweden, Norway, Denmark and Finland. That corresponds to 297,500 trades per day. The number of customers at the end of April was 1,421,600 which is 32,900 more than previous month. Net savings for the month was SEK 9.3 billion and the savings capital was SEK 677 billion. Lending amounted to SEK 22.6 billion at the end of April.[][][] April March Change  April Change  2021[1] 2021 one month 2020 one yearSavings &

Epiroc completes acquisition of software company for increased mine productivity

Stockholm, Sweden: Epiroc, a leading productivity and sustainability partner for the mining and infrastructure industries, has completed the acquisition of MineRP, a software company specializing in increasing productivity for mines through integrated planning, execution and analytics.MineRP has offices in South Africa, Canada, Australia and Chile. The company supports large and medium-sized mines globally in strengthening and optimizing their operational efficiency by providing a leading software platform solution that integrates all technical mining data and other information such as

Jan Krepp appointed new CEO of HENT Sverige

The Ratos-owned construction contractor HENT has recruited Jan Krepp as CEO of its Swedish subsidiary. Jan will focus on strengthening the Swedish organisation in order to increase the company’s profitability and respond to growing demand for HENT’s services in the Swedish market.“We needed to strengthen HENT Sverige AB’s management team in order to move forward. We have a clear target to increase our sales – and improve our earnings. Until today, the company was run by the management team in Norway, but we have identified a need to appoint a CEO in Sweden. And we have succeeded in doing so

Nightingale restructures its Management Team and establishes strategic partnership with Reaktor

Company Release 4 May 2021 at 9:30 a.m. (Finnish time) Nightingale Health Oyj restructures its Management Team and announces a strategic partnership with Reaktor to accelerate the implementation of its global expansion plan. The company’s Chief R&D Officer Dr. Salla Ruosaari has been appointed to lead the company’s product organization, and the company’s Chief Product Officer Osma Ahvenlampi will be leaving the company to pursue other career opportunities. In her role, Ruosaari is responsible for developing services based on the company’s Health Data Platform and delivering such

Reaktor becomes strategic partner of Nightingale to accelerate international growth

Press release 4 May 2021 at 9:30 a.m. (Finnish time) Nightingale and Reaktor, one of Europe’s leading providers of software development and digital design services, agreed on a collaboration regarding the development of Nightingale’s digital preventive health services. The comprehensive strategic partnership intends to support Nightingale’s fast international growth and increase Nightingale’s ability to scale the offering of its digital health solutions globally to its customers, including the ongoing partnerships in Finland with Terveystalo and in Japan with Mitsui and its subsidiary.

Clavister recruits Mats Wenner as VP Global Account Sales

Örnsköldsvik, Sweden, May 4, 2021. Clavister, a leader in high-performance cybersecurity solutions, announces today the appointment of Mats Wenner for the role of Vice President of Global Account Sales.As part of its continuous growth strategy, Clavister is strengthening the company's global account sales team to drive additional business and growth on the back of a good business momentum, especially within the 5G Security and Service Provider markets. "We are very pleased to welcome Mats Wenner in the role of Vice President of Global Account Sales. Mats brings a wealth of experience to

Realheart to present international research at two conferences this summer

Realheart collaborates with several international researchers to develop the world's first artificial four-chamber heart. Results from two such research studies will be presented at scientific conferences in Washington, DC, June 10-12 and Milan July 11-14. Both focus on researching how the product performs in different scenarios.‘’This research is incredibly important for understanding how Realheart TAH performs and identifying any areas that need improvement. These are collaborations at the absolute forefront of research together with experts who possess unique cutting-edge expertise. We

Scandinavian ChemoTech AB - Interim report Q1 January – March 2021 Executive Summary of the first quarter

First quarter · Net sales amounted to kSEK 25 (90) · The order book amounted to kSEK 422 at the end of the first quarter · Profit before tax amounted to kSEK -2 785 (-3 464) · Earnings per share amounted to SEK -0,33 (-1,02) · Cash flow from operating activities totaled to kSEK -5 564 (-4 120) Important events during the quarter · ChemoTech receives a final injunction from the European Patent Office that the patent for the Company’s innovation for TSE treatment of skeletal metastases and deep seated tumours will be granted · ChemoTech was added approximately SEK

2020 Bulkers Ltd. (2020) – Notification of flagging

Reference is made to the press release relating to the contemplated secondary placing of shares in 2020 Bulkers Ltd. (the “Company”) dated 3 May 2021. Drew Holdings Ltd (“Drew”) have sold a total of 1,900,000 shares and Ubon Partners AS (“Ubon”) have sold a total of 1,250,000 shares in the Company at a price of NOK 103.00 per share. After the sale, Drew and Tor Olav Troim will hold a total of 5,502,778 shares and Ubon will hold 784,084 shares representing 24.8% and 3.5% of the share capital and voting rights in the Company, respectively. This information is subject to the disclosure

Annual report 2020 for Initiator Pharma A/S

Initiator Pharma’s annual report for 2020 is now available on the company´s home page http://initiatorpharma.com/investors/financial-reports/ For more information about Initiator Pharma, please contact: Claus Elsborg Olesen, CEOTelephone number: +45 6126 0035 E-mail: ceo@initiatorpharma.com About Initiator Pharma Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company’s main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. The

Trading Statement for 1 January – 31 March 2021

Company Announcement 6/2021 HusCompagniet generates solid growth in both revenue and EBITA in line with expectations. Sales rates were higher than expected, and consequently, sales commissions increased in Q1 2021. The higher than expected sales rate continued in April, leading to an upgrade of the financial outlook for 2021 to a revenue level of DKK 4,100 – 4,250 million and an EBITA of DKK 360-370 million. “I’m very pleased with the strong results for the first quarter of 2021, showing improvements in all of our segments year-on-year, especially in our detached market. The overall

Formica Capital new majority owner of Rototec Group

Formica Capital acquires Rototec Group from Intera Fund II Ky and the company’s management. Rototec is Europe’s largest provider of geoenergy solutions and has shown strong profitable growth through a combination of entrepreneurship and active M&A. Rototec is Formica’s fourth investment within the shift to a globally sustainable energy system. The company’s management will remain as significant minority owners. Rototec is the market leader in geoenergy solutions for mid-sized and large properties, managing Europe’s largest drilling equipment fleet for geoenergy in

Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field

Lund, Sweden, May 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Under the agreement, Alligator will employ its proprietary antibody generation technologies in collaboration with BioArctic to develop new product candidates.“We are very pleased that BioArctic has recognized the power of

Farxiga approved in the US for CKD

4 May 2021 07:00 BST Farxiga approved in the US for the treatment of chronic kidneydisease in patients at risk of progression with and without type-2 diabetes Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death AstraZeneca's Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US

Concentric AB partners with a global leader in driveline technology to develop a new electric oil pump for advanced start/stop capability

Concentric AB has partnered with a global Tier 1 manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles to develop a new fully electric oil pump for use within their “start/stop” technology. Production will start in 2022 and sales revenues from this new contract are estimated to be worth MSEK 45 over the next five years. Advanced “start/stop” technology will be offered as an option across their entire range of transmissions and will enable a reduction in CO\2\ emissions of up to 6% in urban applications. This new electric oil pump also uses

Moberg Pharma’s Interim report for January – March 2021 to be published on May 11 - Invitation to teleconference

STOCKHOLM, May 4[th], 2021 - On May 11[th], 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for January – March 2021. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English. Date:             May 11[th], 2021Time:             3:00 pm (CET) To participate in the conference, please dial in on any number below before the start of the call:

Cloetta launches candy containing 50% fruit

Cloetta’s fruit-based candy, which contains 50% fruit, is a major innovation for 2021 that has been launched across markets under the company’s existing local candy brand portfolio. The product delivers on key consumer trends and is an important part of Cloetta’s innovation strategy to drive organic growth and profitability within the Branded packaged product segment.Consumers are increasingly looking for products with more natural ingredients and positive health benefits. However, it is challenging to develop a product that contains a high level of fruit yet meets the consumers’

TYRI invests an additional €197K EUR ($234K USD) in its EMC laboratory "Now all tests can be carried out in house at TYRI – saving time and money"

TYRI, a world leader in lighting for machinery, continues to invest in the future as they now finance an additional €197K to make possible the ability to do more tests in their own in their EMC laboratory in Gothenburg. With the new investment, they are now able to also measure how their work lights are affected by external interference factors such as power lines, cell towers or the electric environment of the vehicle.When TYRI built their EMC laboratory, the aim was to measure whether their lights interfered with other electronic equipment on board a machine. However, the goal was always

There are no items matching the current filter
There are no more items matching the current filter
Back to top